Project Grant R21MH135361
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$429K
Federal Agency
National Institute of Mental Health
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
William Penn Annex West, PA 19107, USA
Similar Awards
The National Institute of Mental Health (NIMH) awarded a 5-year, $706,404 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Thomas Jefferson University to study the pathophysiological roles of protein-protein interactions at excitatory synapses and their modifications in schizophrenia.
The key objectives are to examine how two specific protein-protein interactions altered in schizophrenia impact nanoscale molecular events to cause NMDA receptor hypofunction, and...
The National Institute of Mental Health (NIMH) awarded a $908,174 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the Lieber Institute for Brain Development to conduct research entitled "Understanding Schizophrenia Risk Mechanisms via Multimodal Analysis of Patient-Derived Neurons and 3D Cortical Organoids and Correlation with Clinical and Cognitive Phenotypes." The project aims to utilize induced pluripotent stem cell (iPSC) technology and 3D cortical organoids to...
This federal Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 - Mental Health Research Grants provides $735,932 in funding to St. Jude Children's Research Hospital Inc. to elucidate the cellular and molecular mechanisms underlying positive symptoms, such as auditory hallucinations, in schizophrenia.
The project aims to characterize thalamocortical disruption and abnormal neuronal activity in the auditory cortex of mouse models harboring genetic risk...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program provides $1,854,632 to The Children's Hospital of Philadelphia (CHOP) from July 2024 to January 2027. The project aims to study the role of mitochondrial function and synaptic activity in the development of schizophrenia, with a focus on iPSC-derived neurons from individuals with 22q11.2 deletion syndrome, a major genetic risk factor for schizophrenia. The...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will fund a $464,750 investigation into the role of tandem repeat variation in the genetic risk of schizophrenia. The goal is to apply innovative algorithms for high-throughput tandem repeat genotyping to large, well-powered schizophrenia cohorts with whole genome sequencing data. This systematic study has the potential to uncover novel genetic risk...
This $388,800 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports a study to examine cognitive and psychiatric endophenotypes associated with rare genetic variants shared between autism spectrum disorder (ASD) and schizophrenia (SCZ). The study, led by researchers at The Trustees of Columbia University in the City of New York, will remotely assess cognition and psychopathology over two time points in...
The National Institute of Mental Health (NIMH) awarded a $128,000 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to the Boston VA Research Institute, Inc. (BVARI) to investigate the neural mechanisms underlying abnormal spontaneous gamma activity (SGA) in schizophrenia and translational mouse models. The research aims to determine if increased SGA in schizophrenia and in mouse models produced by ketamine administration and optogenetic stimulation of...
The National Institute of Mental Health (NIMH) awarded a $9,921,938 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to The Johns Hopkins University. The grant aims to study the impact of the olfactory system on higher brain function and schizophrenia. Key objectives include:
Defining how olfactory epithelium (OE) perturbation, such as chronic local inflammation, elicits neuronal alterations in the OE and olfactory bulb, leading to behavioral...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants (CFDA 93.242) program, provides $826,675 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research aimed at improving cognitive deficits in psychotic disorders. The key objectives are to:
Derive a quantitative structure-activity relationship to optimize the enhancement of the ARC protein, which plays a key role in...
This $245,625 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), is supporting the development of a preclinical therapeutic platform to investigate GABAA alpha5 receptor positive allosteric modulators for improving cognitive function in schizophrenia. The research aims to remediate excitation-inhibition imbalances in hippocampal neural circuitry that contribute to cognitive deficits in this disorder. The...